Eamon Brady is currently the CEO of WhiteSwell, a company focused on advancing treatment for acute decompensated heart failure. Prior to this, Brady was the CEO and Co-Founder of Neuravi before it was acquired by Johnson & Johnson, where Eamon then served as the CEO of the Neuravi division. With previous experience in companies like Abbott Vascular and MedNova Ltd, Brady has a strong background in R&D and new ventures within the medical industry.
July, 2018 - present